Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Stryker (NYSE:SYK - Get Rating) had its price target decreased by equities researchers at BTIG Research from $244.00 to $238.00 in a research note issued on Tuesday, The Fly reports. BTIG Research's price target would suggest a potential upside of 16.80% from the stock's current price.

A number of other research analysts have also recently commented on SYK. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research note on Monday. Morgan Stanley dropped their target price on shares of Stryker from $270.00 to $220.00 and set an "equal weight" rating for the company in a report on Friday, July 15th. Citigroup lowered their price objective on shares of Stryker from $310.00 to $280.00 in a report on Tuesday, May 17th. Stifel Nicolaus lowered their price objective on shares of Stryker from $285.00 to $245.00 in a report on Monday, July 18th. Finally, Truist Financial raised their price objective on shares of Stryker to $220.00 and gave the stock an "outperform" rating in a report on Wednesday, July 27th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $255.57.Stryker Stock Performance

Shares of SYK opened at $203.76 on Tuesday. The firm has a market capitalization of $77.05 billion, a P/E ratio of 37.52, a P/E/G ratio of 2.47 and a beta of 1.03. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.15 and a current ratio of 2.00. The stock has a 50 day moving average price of $207.53 and a two-hundred day moving average price of $232.66. Stryker has a 52 week low of $188.84 and a 52 week high of $281.16.

Stryker (NYSE:SYK - Get Rating) last posted its earnings results on Tuesday, July 26th. The medical technology company reported $2.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same period in the previous year, the company posted $2.25 EPS. Equities analysts forecast that Stryker will post 9.38 earnings per share for the current fiscal year. Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Claremont Financial Group Inc. purchased a new stake in Stryker in the 1st quarter worth $25,000. Exane Derivatives purchased a new stake in Stryker in the 1st quarter worth $27,000. Princeton Global Asset Management LLC lifted its stake in Stryker by 1,212.5% in the 1st quarter. Princeton Global Asset Management LLC now owns 105 shares of the medical technology company's stock worth $28,000 after purchasing an additional 97 shares in the last quarter. Dixon Hughes Goodman Wealth Advisors LLC lifted its stake in Stryker by 10,700.0% in the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 108 shares of the medical technology company's stock worth $29,000 after purchasing an additional 107 shares in the last quarter. Finally, Holloway Wealth Management LLC purchased a new stake in Stryker in the 1st quarter worth $33,000. Hedge funds and other institutional investors own 76.44% of the company's stock. About Stryker (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.Read MoreGet a free copy of the StockNews.com research report on Stryker (SYK)MarketBeat Podcast: Stock Market, Bad News is Good News Forget Bitcoin, Block’s Ecosystems are the Real Growth Drivers What Does an Inverted Yield Curve Mean For You?SPY vs. QQQ: Which ETF Wins in 2022?Could Snap Stock Rebound As Management Restructures?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Michael Wang of Prometheus Alternative Investments discusses how individuals should approach their portfolios as the summer rally seems to have fizzled.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.